Gary Nachman Analyst Performance

Managing Director BioPharma/Biotechnology at Raymond James Financial

Gary Nachman is a stock analyst at Raymond James Financial focused in the medical sector, covering 20 publicly traded companies. Over the past year, Gary Nachman has issued 7 stock ratings, including strong buy, buy, and hold recommendations. While full access to Gary Nachman's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Gary Nachman's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 49 Last 10 Years
Buy Recommendations: 62.50% 30 Buy Ratings
Companies Covered: 20 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	2.1%	1 ratings
Buy	60.4%	29 ratings
Hold	31.3%	15 ratings
Sell	6.3%	3 ratings

Out of 48 total stock ratings issued by Gary Nachman at Raymond James Financial, the majority (60.4%) have been Buy recommendations, followed by 31.3% Hold, 6.3% Sell, and 2.1% Strong Buy.

Best & Worst Calls

Best Call
0000.0%
HZNP
Aug 2019
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
000.0%
MNK
Aug 2019
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	85.0% of companies on NASDAQ	17 companies
NYSE	15.0% of companies on NYSE	3 companies

Gary Nachman, an analyst at Raymond James Financial, currently covers 20 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 19 companies	95.0%
	Miscellaneous 1 company	5.0%

Gary Nachman of Raymond James Financial specializes in stock coverage within the Medical sector, with additional focus on companies.

Coverage Industries

Industry	Percentage
PHARMACEUTICAL PREPARATIONS 8 companies	40.0%
MED - BIOMED/GENE 7 companies	35.0%
LARGE CAP PHARMA 1 company	5.0%
MED PRODUCTS 1 company	5.0%
MED - DRUGS 1 company	5.0%
MED - GENERIC DRG 1 company	5.0%
Miscellaneous 1 company	5.0%

About Gary Nachman

Gary Nachman joined Raymond James in 2023 as a senior analyst covering biotechnology and specialty pharmaceuticals. Prior to joining the firm, he was most recently a managing director covering biopharma and specialty pharma at BMO Capital Markets for seven years. Before that, he was a senior analyst covering specialty pharma at Goldman Sachs, Susquehanna International Group, Leerink Swann and Morgan Stanley. Before getting into equity research, Gary spent a few years in the pharmaceutical industry at Merck, where he was a manager in the financial evaluations group at Merck‐Medco. Gary earned his MBA from Columbia Business School and a B.S. in accounting from Binghamton University, where he graduated magna cum laude.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
AMGN Amgen	9/3/2025	Initiated Coverage	$286.07		Market Perform
ABBV AbbVie	8/25/2025	Reiterated Rating	$207.74		Outperform
VERU Veru	8/13/2025	Lower Price Target	$3.17	$20.00	Outperform
ABBV AbbVie	8/1/2025	Boost Price Target	$189.02	$236.00	Outperform
LENZ LENZ Therapeutics	7/31/2025	Boost Price Target	$30.98	$40.00	Outperform
IONS Ionis Pharmaceuticals	7/31/2025	Boost Price Target	$43.35	$64.00	Strong-Buy
ABBV AbbVie	2/3/2025	Reiterated Rating	$183.90	$220.00	Outperform

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.